Trials / Recruiting
RecruitingNCT07219173
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Uncontrolled Moderate to Severe Asthma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 531 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brenipatide | Administered SC |
| DRUG | Brenipatide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2025-10-22
- Primary completion
- 2028-04-01
- Completion
- 2028-06-01
- First posted
- 2025-10-21
- Last updated
- 2026-04-17
Locations
121 sites across 12 countries: United States, Argentina, Brazil, Canada, China, France, Germany, India, Japan, Mexico, Netherlands, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07219173. Inclusion in this directory is not an endorsement.